20th July 2015
Microbial expression systems such as Escherichia coli (E. coli) are still a popular choice for biotherapeutic production. Lower manufacturing costs, high-productivity rates, and their FDA-approved status for human applications make E. coli an attractive, economical option for Fab, vaccine, and peptide hormone therapies.
Click on the PDF icon above to download the full application note.